Collplant Biotechnologies Ltd
CLGN0.800USD
+0.050+6.65%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
10.22MMarket Cap
LossP/E TTM
More Details of Collplant Biotechnologies Ltd Company
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Collplant Biotechnologies Ltd Info
Ticker SymbolCLGN
Company nameCollplant Biotechnologies Ltd
IPO dateSep 01, 1993
CEORotem (Eran)
Number of employees57
Security typeOrdinary Share
Fiscal year-endSep 01
Address4 Oppenheimer Street
CityREHOVOT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code7670104
Phone972732325600
Websitehttps://www.collplant.com
Ticker SymbolCLGN
IPO dateSep 01, 1993
CEORotem (Eran)
Company Executives of Collplant Biotechnologies Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
31.14K
--
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
2.00K
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Founder, Chief Scientist
Founder, Chief Scientist
--
--
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
--
--
Dr. Nadav Orr
Dr. Nadav Orr
Vice President - Research & Development
Vice President - Research & Development
--
--
Dr. Ilana Belzer, Ph.D.
Dr. Ilana Belzer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gili Hart
Dr. Gili Hart
Independent Director
Independent Director
--
--
Dr. Elan Penn, Ph.D.
Dr. Elan Penn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Roger J. Pomerantz, M.D.
Dr. Roger J. Pomerantz, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
31.14K
--
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
2.00K
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Founder, Chief Scientist
Founder, Chief Scientist
--
--
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
--
--
Dr. Nadav Orr
Dr. Nadav Orr
Vice President - Research & Development
Vice President - Research & Development
--
--
Dr. Ilana Belzer, Ph.D.
Dr. Ilana Belzer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2023Q2
FY2022
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Revenues from the sales of goods
179.00K
0.00%
By RegionUSD
Name
Revenue
Proportion
Northern America
159.00K
88.83%
Europe
20.00K
11.17%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Revenues from the sales of goods
179.00K
0.00%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sagy (Ami)
12.81%
Loewenbaum (George Walter II)
9.83%
St. Denis J. Villere & Company, LLC
4.75%
Pinnacle Associates Ltd.
4.36%
Loewenbaum (Lilian Shaw)
3.18%
Other
65.06%
Shareholders
Shareholders
Proportion
Sagy (Ami)
12.81%
Loewenbaum (George Walter II)
9.83%
St. Denis J. Villere & Company, LLC
4.75%
Pinnacle Associates Ltd.
4.36%
Loewenbaum (Lilian Shaw)
3.18%
Other
65.06%
Shareholder Types
Shareholders
Proportion
Individual Investor
29.81%
Investment Advisor
7.56%
Investment Advisor/Hedge Fund
5.38%
Hedge Fund
1.74%
Research Firm
0.14%
Family Office
0.13%
Other
55.25%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
34
1.82M
18.05%
--
2025Q3
36
1.82M
18.09%
-351.44K
2025Q2
36
2.17M
13.51%
+569.42K
2025Q1
36
2.09M
19.82%
-180.41K
2024Q4
38
2.54M
24.36%
-57.22K
2024Q3
40
2.59M
23.16%
+143.75K
2024Q2
40
2.45M
24.33%
+72.69K
2024Q1
40
2.38M
24.25%
-401.71K
2023Q4
45
2.39M
26.23%
-101.34K
2023Q3
46
2.49M
28.02%
-60.71K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sagy (Ami)
1.64M
12.81%
-306.10K
-15.75%
Nov 19, 2025
Loewenbaum (George Walter II)
1.26M
9.83%
--
--
Nov 06, 2025
St. Denis J. Villere & Company, LLC
588.72K
4.61%
+41.85K
+7.65%
Sep 30, 2025
Pinnacle Associates Ltd.
507.19K
3.97%
--
--
Sep 30, 2025
Loewenbaum (Lilian Shaw)
406.29K
3.18%
-245.19K
-37.64%
Nov 06, 2025
Evans (Hugh M)
377.43K
2.95%
-1.00
-0.00%
Mar 15, 2025
Roumell Asset Management, L.L.C.
276.43K
2.16%
-38.86K
-12.32%
Jun 30, 2024
AMH Equity, Ltd.
200.00K
1.57%
+39.15K
+24.34%
Sep 30, 2025
Brown Advisory
118.73K
0.93%
+7.55K
+6.79%
Sep 30, 2025
Benjamin F. Edwards & Company, Inc.
39.76K
0.31%
-10.69K
-21.19%
Jun 30, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
